Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

29.40 -0.04 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 250,172
Open 29.40
Bid (Size) 28.55 (1)
Ask (Size) 29.31 (9)
Prev. Close 29.44
Today's Range 28.86 - 30.05
52wk Range 13.15 - 39.85
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Kymera Therapeutics to Participate in Upcoming June Investor Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
From Kymera Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+18.36%
+18.36%
1 Month
-6.61%
-6.61%
3 Month
-8.33%
-8.33%
6 Month
+1.45%
+1.45%
1 Year
+106.03%
+106.03%

More News

Read More
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Kymera Therapeutics
Via Benzinga
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Growth Stocks That Could Double Your Money in 2023
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
Via InvestorPlace
Join These Motley Fool Investors for "The Market Cap Game Show"
Via The Motley Fool
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
Via Benzinga
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
From Kymera Therapeutics, Inc.
Via GlobeNewswire
X-Chem and Kymera Expand Existing Partnership
From X-Chem
Via Business Wire
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Appoints Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Kymera Therapeutics, Inc.
Via GlobeNewswire
7 Perfect Presents to Gift Your 2023 Stock Portfolio
Via InvestorPlace
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Via The Motley Fool
Dear DS Stock Fans, Mark Your Calendars for Dec. 23
Via InvestorPlace
Why Is SOFI Stock Up 7% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.